JP2011074021A - Oral composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an oral composition, more precisely, the oral composition for ameliorating blood vessel state such as lowering blood vessel age by improving elasticity, etc., of the blood vessel. <P>SOLUTION: The oral composition is prepared by combining an extract of pine bark, reduced coenzyme Q10 and an extract of Eucommia ulmoides. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  The present invention relates to oral compositions. More specifically, the present invention relates to an oral composition used for the purpose of improving vascular conditions, such as improving the elasticity of blood vessels and reducing the age of blood vessels.

  With the aging of society, adult diseases are becoming an increasingly important social issue. Symptoms caused by adult diseases, especially blood-related diseases such as hypertension, arteriosclerosis, pulmonary hypertension, myocardial infarction, cerebral infarction, pulmonary infarction, vasospasm after subarachnoid hemorrhage, etc. Moreover, preventing the occurrence of diseases caused by stiffening is an important issue today, especially in the aged society where the need for self-medication is advocated.

  The progress of damage and aging of blood vessels varies from person to person. Therefore, it is important to directly measure the aging degree of blood vessels, but in recent years, the arterial pressure fluctuation caused by heartbeats, that is, the pulse wave is measured and analyzed to measure the aging degree of blood vessels noninvasively and quantitatively. It has become possible to evaluate. Identification of pulse wave velocity (PWV), which is the velocity at which the pulse wave travels inside the blood vessel, augmentation index (AIx) reflecting peripheral total vascular resistance, or acceleration pulse wave, which is the second derivative of fingertip volume wave Waveform components and numerical indices composed of them show a certain change with aging (Non-patent Documents 1 and 2), so the concept of “blood vessel age” based on the reference value in each age has spread. It's getting on. In recent clinical trials, there are an increasing number of reports showing that PWV, AIx, and the like are useful as predictors of cardiovascular disease risk (see Non-Patent Documents 3 and 4). Therefore, a component that can directly improve a pulse wave-related index such as PWV and AIx and maintain the “blood vessel age” in an appropriate range is likely to be useful for the prevention and treatment of cardiovascular diseases.

  Conventionally, an acidic water-soluble fraction contained in buckwheat tea (Non-patent Document 5), button buds that are sericaceae plants (Non-patent Document 6), proanthocyanidins (Patent Document 1), and nakanaka leaf water extract (patent) Literature 2), Hop (Patent Literature 3), and a water-soluble solvent extract of Murasaki sweet potato (Patent Literature 4) are known to have an effect of softening vascular smooth muscle.

  However, it is unclear whether a substance having such a vasorelaxant action is effective in improving the vascular condition, and in order to achieve the purpose of reducing the risk of cardiovascular disease, a substance having an action to improve the vascular condition Pioneering is necessary.

Schiffrin, Am.J.Hypertens., 17: 395,2004 Takazawa, et al., Hypertension 32: 365, 1998 Boutouyrie, et al., Hypertension 39: 10,2002 London et al., Hypertension 38: 434, 2001 ITO EN News Release “May 10, 2006 Confirmed for the first time that ingredients contained in buckwheat tea have vasodilatory effects: Announced at the 60th Annual Meeting of the Japanese Society of Nutrition and Food (May 20-21)” Search on September 20, 2009), Internet <http://www.itoen.co.jp/news/2006/051001.html> TAKARA BIO INC. News Release “Confirmed that cerebral button-bottoms have vasodilatory effects, 2009.8.26” (searched on September 20, 2009), Internet <http://www.takara-bio.co .jp / news / 2009/08 / 26.htm>

JP 2004-123707 A JP 2006-137715 A JP-A-2005-104951 JP 2001-145471 A

  An object of the present invention is to provide an oral composition used for the purpose of improving vascular conditions, such as improving the elasticity of blood vessels and reducing the age of blood vessels. More specifically, an object of the present invention is to provide an oral composition excellent in vascular condition improvement effect so as to significantly suppress the onset of diseases related to blood vessels such as hypertension and arteriosclerosis.

  The present inventor has repeatedly studied to solve the above-mentioned problems. As a result, a composition containing a combination of pine bark extract, reduced coenzyme Q10 and Tochu extract has improved blood vessel elasticity and the like. Found that it is excellent in the effect of improving the vascular condition, such as decreasing the age, and the composition containing these components exhibits an excellent effect in the prevention and improvement of cardiovascular diseases as a vascular condition improving agent. I was convinced that

The present invention has been completed based on such findings, and includes the following aspects.
(1) An oral composition containing a pine bark extract, reduced coenzyme Q10, and a Tochu extract.
(2) The oral composition according to (1), containing 2 to 10 parts by weight of reduced coenzyme Q10 and 1 to 10 parts by weight of Tochu extract with respect to 1 part by weight of pine bark extract.
(3) The oral composition described in (1) or (2), which is a vascular condition improving composition.

  The oral composition of the present invention containing pine bark extract, reduced coenzyme Q10 and Tochu extract is continuously ingested to improve the elasticity of blood vessels and lower the age of blood vessels. It is excellent in the effect of improving the vascular condition. For this reason, the oral composition of the present invention not only helps maintain and promote health by improving the vascular condition associated with aging, but also prevents or improves cardiovascular diseases such as hypertension and arteriosclerosis. It can be used effectively.

In Experimental Example 1, 14 subjects were subjected to (a) peripheral vascular health. Before ingestion, 2. 2 weeks after ingestion, 3. 4 weeks after ingestion, 4. It is the figure which measured on the 2nd week after completion | finish of ingestion, respectively, and showed the influence on the vascular state by the oral composition (capsule) of this invention. In Experimental Example 1, 14 subjects were tested, and (b) vascular aging rate was: Before ingestion, 2. 2 weeks after ingestion, 3. 4 weeks after ingestion, 4. It is the figure which measured on the 2nd week after completion | finish of ingestion, respectively, and showed the influence on the vascular state by the oral composition (capsule) of this invention. In the figure, * indicates that there is a significant difference at a risk rate of 5% (the same applies to FIGS. 3 and 6). Targeting 14 subjects in Experimental Example 1, (c) Average waveform type of acceleration pulse wave Before ingestion, 2. 2 weeks after ingestion, 3. 4 weeks after ingestion, 4. It is the figure which measured on the 2nd week after completion | finish of ingestion, respectively, and showed the influence on the vascular state by the oral composition (capsule) of this invention. A vertical axis | shaft is what averaged the numerical value (I-VI) of a waveform type by a test subject, and shows that blood-vessel age is younger, so that a numerical value is low. In Experimental Example 1, 14 subjects were subjected to (d) differential pulse wave index. Before ingestion, 2. 2 weeks after ingestion, 3. 4 weeks after ingestion, 4. It is the figure which measured on the 2nd week after completion | finish of ingestion, respectively, and showed the influence on the vascular state by the oral composition (capsule) of this invention. In Experimental Example 1, 14 subjects were subject to (e) stroke intensity. Before ingestion, 2. 2 weeks after ingestion, 3. 4 weeks after ingestion, 4. It is the figure which measured on the 2nd week after completion | finish of ingestion, respectively, and showed the influence on the vascular state by the oral composition (capsule) of this invention. A vertical axis | shaft shows the absolute value of the value which averaged each patient's output intensity (graph display: -20--120) measured with the autonomic nerve analysis acceleration pulse wave meter with the test subject. For this reason, it shows that a blood vessel state is so favorable that a numerical value is large. In Experimental Example 1, 14 subjects were subjected to (f) arterial vascular elasticity. Before ingestion, 2. 2 weeks after ingestion, 3. 4 weeks after ingestion, 4. It is the figure which measured on the 2nd week after completion | finish of ingestion, respectively, and showed the influence on the vascular state by the oral composition (capsule) of this invention. A vertical axis | shaft shows the absolute value of the value which averaged each arterial vascular elasticity (graph display: -150- + 20) measured with the autonomic nerve analysis acceleration pulse wave meter with the test subject. For this reason, it shows that a vascular state is so favorable that a numerical value is low.

  The oral composition of the present invention contains a pine bark extract, reduced coenzyme Q10, and a Tochu extract.

(1) Pine bark extract Pine bark extract is a natural functional material extracted from pine bark and contains about 40 kinds of organic acids and other physiologically active ingredients including procyanidins. Here, procyanidin is a polymer of catechin and is one of secondary metabolites that most plants have. When procyanidins are polymerized, their useful physiological activities are increased, and further, useful physiological activities that are not found in the catechin monomer are generated.

  The pine bark belongs to the pines of French coastal pine (Pinus Martima), larch, Japanese black pine, Japanese red pine, Japanese pine, Japanese pine, Korean pine, Japanese pine, Ryukyu pine, Utsukushima pine, Japanese pine, white pine, and Canada's Quebec aneda. Mention may be made of the bark of plants. Preferred is the bark of French maritime pine (Pinus Martima), which is a marine pine that grows on a part of the Atlantic coast of southern France.

  The pine bark extract is prepared by a method of extracting a fraction rich in procyanidins from pine bark, and is not particularly limited as long as it is used. For example, a solvent extraction method, a supercritical fluid extraction method, or the like is used.

  The solvent extraction method is performed by extracting pine bark with water or an organic solvent. When using water, it is preferable to use warm water or hot water. As an organic solvent used for extraction, an organic solvent that is acceptable for the production of food or drugs is used. For example, methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, acetone, hexane, cyclohexane , Propylene glycol, hydrous ethanol, hydrous propylene glycol, ethyl methyl ketone, glycerin, methyl acetate, ethyl acetate, diethyl ether, dichloromethane, edible oils and fats, 1,1,1,2-tetrafluoroethane, and 1,1,2- Trichloroethene is mentioned. These water and organic solvent may be used alone or in combination. Preferably, water, hot water, ethanol, hydrous ethanol, and hydrous propylene glycol are preferably used. In addition, it is preferable to add salts, such as sodium chloride, to an extract from the point which improves extraction efficiency.

  The supercritical fluid extraction method is performed by extracting using a fluid (supercritical fluid) in a state exceeding the critical point (critical temperature, critical pressure) of the gas-liquid of the substance. Examples of the supercritical fluid include carbon dioxide, ethylene, propane, nitrous oxide (laughing gas), and preferably carbon dioxide.

  In addition to the above method, the pine bark extract can also be prepared by performing a liquid carbon dioxide batch method, a liquid carbon dioxide reflux method, a supercritical carbon dioxide reflux method, or the like.

  The pine bark extract can be used as a concentrate, a viscous substance, or a solid obtained by concentration and / or lyophilization, if necessary.

  The pine bark extract thus prepared preferably contains 35% by weight or more of procyanidins. More preferably, it is a pine bark extract containing procyanidins of 60% by weight or more.

  In addition, such a pine bark extract can be obtained commercially, for example, the commercial item sold from Toyo Shinyaku Co., Ltd. can be used.

  The content of the pine bark extract in the oral composition of the present invention is not limited, but is preferably 3% by weight or more in terms of solid matter. Preferably it is 3 to 25 weight%, More preferably, it is 5 to 20 weight%.

(2) Reduced coenzyme Q10
There are two types of coenzyme Q10, oxidized and reduced. Of these, reduced coenzyme Q10 is preferably used in the present invention.

  Reduced coenzyme Q10 can be obtained commercially, and for example, a commercial product sold by Kaneka Corporation can be used.

  In order for the oral composition of the present invention to exhibit a higher effect, the reduced coenzyme Q10 is 2 to 10 parts per 1 part by weight (in terms of solids) of the pine bark extract blended in the oral composition. It is preferable to mix | blend in the ratio of a weight part. The amount is more preferably 2 to 8 parts by weight, particularly preferably 3 to 6 parts by weight.

  When this is converted into a ratio to 1 part by weight of procyanidin contained in the pine bark extract, the blending ratio of reduced coenzyme Q10 is 2.5 to 20 parts by weight with respect to 1 part by weight of procyanidins, more preferably 2 0.5 to 16 parts by weight, particularly preferably 3.5 to 10 parts by weight.

(3) Tochu extract The Tochu extract is an extract of Eucommia ulmoides, and its part is not particularly limited, but it is preferable to use leaves from the viewpoint of obtaining a high yield.

  Although the extraction method of a Tochu extract is not specifically limited, For example, a solvent extraction method, a supercritical fluid extraction method, etc. are used.

  The solvent extraction method is performed by extracting Tochu with water or an organic solvent. When using water, it is preferable to use warm water or hot water. As an organic solvent used for extraction, an organic solvent that is acceptable for the production of food or drugs is used. For example, methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, acetone, hexane, cyclohexane , Propylene glycol, hydrous ethanol, hydrous propylene glycol, ethyl methyl ketone, glycerin, methyl acetate, ethyl acetate, diethyl ether, dichloromethane, edible oils and fats, 1,1,1,2-tetrafluoroethane, and 1,1,2- Trichloroethene is mentioned. These water and organic solvent may be used alone or in combination. Preferably, water, hot water, ethanol, hydrous ethanol, and hydrous propylene glycol are preferably used.

  The chunaka leaf used for the preparation of the chuchu extract may be produced by cultivation or collected from nature. For example, fresh leaves before the fall of the current year are used, and fresh leaves from April to October, preferably from May to August, more preferably from June to August can be used. The nakanaka leaf used for the water extraction may be a nakanaka leaf before harvesting and before drying, or a nakanaka leaf prepared by processing the nakanaka leaf. The nakanaka extract used in the present invention is preferably prepared by a production method comprising a step of steaming cocoon leaves, a step of twisting nakanaka leaves, a step of extracting nakanaka leaves with water, and a step of concentrating the extract. Is done. That is, the nakanaka leaf used in the present invention may be a nakanaka tea leaf prepared by a method including a step of steaming the cocoon leaf and a step of twisting the nakanaka leaf.

  Here, the steaming process of the cocoon leaves can be carried out by a method usually performed in the technical field using a commercially available steamer or an autoclave. For example, it is possible to heat-treat the green leaves by spreading the green leaves on a net conveyor and passing it through a processing chamber filled with non-pressure steam supplied from a boiler. The steaming temperature is not particularly limited, but may be appropriately selected within the range of 90 to 120 ° C., for example, depending on the size of the potato. Further, the steaming time can be appropriately selected within a range of 10 to 240 seconds. Moreover, the vapor | steam amount to be used can be suitably selected, for example in the range of 200-70 L / min. The treatment amount of the steamed leaves is not particularly limited depending on the moisture content of the fresh leaves, but may be appropriately selected within a range of 3 to 10 kg / min, for example. This steaming process makes it easier to keep the ingredients of the fresh-leaved leaves by inactivating the enzyme that changes the brown-colored leaves, and the softening of the fresh leaves makes it easier to perform the subsequent twisting process. It brings about effects such as.

  The twisting process can be performed using, for example, a commercially available twisting machine, roughing machine, or intermediate hammering machine. For example, as a commercially available twister, Terada Seisakusho Co., Ltd., a twister 60 kg type etc. can be used. By this step, the moisture in the Tochu leaf is uniformly prepared while removing excess moisture, and further, it is easy to extract the components unique to Tochu. Although this process can be performed under heating as necessary, it is preferably performed without heating. The time required for this step is not particularly limited, but can be appropriately selected within a range of, for example, 10 to 80 minutes. The treatment amount of the cocoon twisted leaves is not particularly limited, but may be appropriately selected within the range of 25 to 40 kg, for example, depending on the moisture content. The water content of the chunaka leaf obtained through this step is, for example, 25 to 40% on a dry basis.

  The method for preparing the chunaka leaf may include a step of roasting the chunaka leaf after the twisting step. The step of roasting the Nakanaka leaves is not particularly limited, but can be performed using, for example, a commercially available roaster. Although the roasting method in this process is not particularly limited, for example, it can be carried out by a hot air rotary drying fired machine manufactured by Yokoyama Seisakusho Co., Ltd. The time required for this step is not particularly limited, but can be appropriately selected within a range of 30 to 50 minutes. The roasting temperature in this step is not particularly limited, but can be appropriately selected within a range of, for example, 100 to 140 ° C. The water content of the chunaka leaf obtained through this step is, for example, 8% or less on a dry basis.

  In the step of obtaining the Tochu extract, for example, an amount of water appropriately selected from 5 to 50 kg can be used per 1 kg of Tochu leaf. The water extraction of the Tochu leaves may be, for example, extraction with hot water at 85 to 105 ° C., preferably 90 to 95 ° C., or the water containing the crushed tochu leaves may be cooled to a lower temperature (for example, 25 to 50 ° C.). , Preferably 30-45 ° C.).

The soot extract thus prepared can be used as a concentrated solution, a viscous substance or a solid obtained by concentration and / or lyophilization, if necessary. In order to exert a high effect, the Tochu extract is 1 to 10 parts by weight in terms of solids with respect to 1 part by weight (in terms of solids) of the pine bark extract blended in the oral composition. It is preferable to mix. More preferably, it is 1-7 weight part, Most preferably, it is 2-4 weight part.

  When this is converted into a ratio to 1 part by weight of procyanidin contained in the pine bark extract, the blending ratio of the Tochu extract is 1.2 to 20 parts by weight, more preferably 1. 2 to 14 parts by weight, particularly preferably 2.5 to 7 parts by weight.

(4) Other components The oral composition of the present invention may contain other components as required in addition to the above components as long as the effects of the present invention are not hindered. For example, acidic water-soluble fractions contained in buckwheat tea (Non-patent Document 1), plant extracts such as button-bellied sorghum (Non-patent Document 2), ester conjugates of chlorogenic acid derivatives and arginine (JP 2006 -298802)), and the like.

  The other components can be appropriately set according to the application and form of the oral composition of the present invention. For example, when used as food or drink or oral medicine, for example, excipients, fillers, binders, thickeners, emulsifiers, lubricants, wetting agents, suspending agents, coloring agents, flavoring agents, and nutritional components These components can be blended according to the purpose.

(5) Oral composition The oral composition of the present invention can be prepared by mixing the above-mentioned components by methods commonly used by those skilled in the art to obtain various forms for oral administration or ingestion.

  The oral composition of the present invention can be prepared as a pharmaceutical composition. Such pharmaceutical compositions are available in various dosage forms such as tablets, capsules (hard capsules, soft capsules), powders, granules, pills, solutions, emulsions, suspensions, solutions, spirits, A syrup, extract, elixir and the like can be used. Such pharmaceutical compositions can contain various commonly used ingredients, such as one or more pharmaceutically acceptable excipients, disintegrants, diluents, lubricants, flavors, colorings. Agents, sweeteners, flavoring agents, suspending agents, wetting agents, emulsifying agents, dispersing agents, adjuvants, preservatives, buffering agents, binders, stabilizers, coating agents and the like. The pharmaceutical composition of the present invention may be in a sustained or sustained release dosage form.

  The dosage of such a pharmaceutical composition can be appropriately selected depending on the administration route, the patient's body shape, age, physical condition, degree of disease, and the like. Although not limited, it can be generally used at a dose of 0.01 to 30 mg / day / adult, preferably 1 to 20 mg / day / adult in terms of the dose of procyanidin contained in the pine bark extract. Moreover, it is 0.02 to 300 mg / day / adult, preferably 2 to 200 mg / day / adult, in terms of the dose of reduced CoQ10, and in terms of the dose of Tochu extract (solid matter). It can be used at a dose of 0.01-300 mg / day / adult, preferably 1-200 mg / day / adult. Administration of the pharmaceutical composition may be a single dose or multiple doses per day.

  The oral composition of the present invention can be prepared as a food composition. The food composition includes a beverage. The food composition can be used as a functional food as it is, and can also be used as a food and drink, a pharmaceutical product, a quasi-drug, a food and drink component, a food additive, and the like.

  Examples of the food composition of the present invention, particularly foods or beverages, include functional foods having a vascular condition improving effect (including foods for specified health use), health foods, general foods (juices, confectionery, processed foods, etc.), Nutritional supplements (such as energy drinks) are included. The food composition of the present invention includes supplements having oral dosage forms such as tablets, capsules (hard capsules, soft capsules), powders, granules, pills, liquids and the like.

  The recommended intake of the food composition can be determined according to the dose of the pharmaceutical composition. Moreover, the food composition may be taken once per day or may be taken multiple times.

  By using the food composition of the present invention, it becomes possible to ingest foods and drinks having an effect of improving vascular conditions on a daily basis, and various diseases associated with vascular sclerosis, such as hypertension, arteriosclerosis, etc. It becomes possible to prevent the onset of various cardiovascular diseases.

  The oral composition of the present invention can be used for the purpose of improving the vascular condition exclusively in the food and medical fields due to the above-described effects.

  Here, the “blood vessel state” is evaluated using, for example, the acceleration pulse wave waveform, differential pulse wave index, stroke strength, arterial vascular elasticity, and peripheral vascular health and vascular aging rate calculated based on these as indices. `` Improvement of vascular condition '' means an improvement in the waveform type of acceleration pulse wave, an increase in differential pulse wave index, a decrease in stroke intensity, an increase in arterial vascular elasticity, and an increase in peripheral vascular health, Means a decrease in blood vessel aging rate.

  The indicators indicating these vascular states can be suitably quantified using, for example, an autonomic nerve analysis acceleration pulse wave meter (APG: Accelerated Photoplethysmography) “Pulse Analyzer Plus / TAS9 (manufactured by YKC group)”. Can be evaluated as an index.

  Hereinafter, although an example of an experiment is given and the present invention is explained, the present invention is not limited to these examples. Unless otherwise specified, “parts” means “parts by weight” and “%” means “% by weight”.

Experimental Example 1 Evaluation of vascular condition improvement effect (1) Preparation of oral composition Reduced coenzyme Q10 60 parts, pine bark extract 20 parts, Tochu Nakaba water extract (Method of Example 1 of JP 2006-137715 A) 40 parts) was dissolved in 157 parts of vegetable oil, 13 parts of glycerin fatty acid ester and 10 parts of beeswax were added thereto to make capsule contents. The prepared contents were encapsulated in a gelatin film according to a conventional method for producing a soft capsule preparation so that the content was 300 mg per piece, and an oral composition (soft capsule) of 475 mg per piece was prepared.

(2) Test method Soft capsules prepared in (1) above (475 mg / 475) for 14 subjects whose peripheral vascular health before ingestion was determined to be 65 points or less out of 100 points, and the vascular condition was poor Individual: About 20 mg of pine bark extract, 60 mg of reduced coenzyme Q10, 40 mg of Tochu-naka water extract) were ingested 1 capsule per day for 1 month, and the effect on vascular condition was confirmed.

  In order to confirm the effect on the vascular condition, the waveform of the fingertip volume pulse wave and acceleration pulse wave is used by using the Accelerated Photoplethysmography (APG) "Pulse Analyzer Plus / TAS9 (YKC group)" From type: (a) peripheral vascular health, (b) vascular aging rate, (c) average waveform type of acceleration pulse wave, (d) differential pulse wave index, (e) stroke intensity, and (f) arterial blood vessel The elasticity was measured. The measurement was performed 4 times before ingestion, 2 weeks after ingestion, 4 weeks after ingestion, and 2 weeks after the end of ingestion.

  The autonomic nerve analysis acceleration pulse wave manual includes (a) peripheral blood vessel health, (b) blood vessel aging rate, (c) average waveform type of acceleration pulse wave, (d) differential pulse wave index, ( The following explanations are given for e) stroke strength and (f) arterial vascular elasticity.

(a) Peripheral vascular health・ Displayed in the range of 0 to 100 points ・ The closer to dark green (right side of the graph), the better ・ Analyze the subject's waveform and score it.

(b) Vascular aging rate・ The subject's average waveform type is quantified in consideration of heart rate, age, etc. ・ Normally about 1.0 to 1.2 is in the appropriate range ・ In 1.0 or less, the aging rate of peripheral blood vessels is higher than the actual aging rate The later, the higher the value, the faster the aging.

(c) Display the average waveform type of acceleration pulse wave and the type of waveform closest to the subject's waveform. Classified by “I II III IV V VI” waveform type.
・ Typical waveforms often seen in the 20s, 30s, 40s, 50s, 60s, and 70s, but there are individual differences.
・ The reconciliation waveform is more ideal than the average waveform for the subject's age.

(d) Differential pulse wave index (a wave): DPI (Differential Pulsewave Index)
・ The moment when the heart contracts ・ Used as a reference value to make comparison easier when observing the waveform ・ It is related to the degree of aging of blood vessels, and this value decreases as aging progresses ・ No correlation with age .
・ 100 or more is desirable (graph display: 0 to 150).

(e) Stroke intensity (b wave): SP (Stress Power)
・ Early systole of heart (negative wave)
・ Represents cardiac output intensity, b wave appears by bounce of a wave ・ Adapts sensitively to changes in arterial pressure (responds to arteriosclerosis)
・ Increased with age ・ Lower value (graph display: -20 to -120)
(f) Arterial vascular elasticity (d wave): BVT (Blood Vessel Tension)
-Late systole (re-decreasing wave) of the heart
・ Adapt sensitively to changes in arterial pressure (responds to arteriosclerosis)
-Represents the flexibility of blood vessels-Decreases with age-The larger the value (graph display: -150 to +20), the better the state of the blood vessels.

(3) Test results
(a) peripheral vascular health, (b) vascular aging rate, (c) average waveform type of acceleration pulse wave, (d) differential pulse wave index, (e) stroke strength, and (f) arterial vascular elasticity The results are shown in FIGS.

  In all subjects (n = 14), (b) vascular aging rate, (c) average waveform type of acceleration pulse wave, (d) differential pulse wave index, (e) stroke intensity, and (f) arterial vascular elasticity In all of the items, a marked improvement effect was seen. On the other hand, in the measurement in the second week after the end of intake, there was a tendency for deterioration in almost all items compared to that during intake. From this, it was confirmed that the oral composition of the present invention can improve the vascular condition and maintain its effect by continuous administration or ingestion.

  From these results, the oral composition of the present invention, when taken orally, peripheral blood vessel health, vascular aging rate, average waveform type of acceleration pulse wave, differential pulse wave index, cardiac strength, arterial vascular elasticity It was suggested that the effect of improving the degree of blood vessels can be expected to prevent aging of blood vessels and rejuvenate blood vessels.

  In addition, when a test similar to the above was performed not only for subjects with poor vascular conditions but also for subjects with poor vascular conditions, the same effects as described above were observed throughout the subjects.

Formulation Examples 1-4
According to the prescription described below, an oral composition of the present invention containing a combination of reduced coenzyme Q10, pine bark extract and tochu leaf extract was prepared.
(Prescription Example 1: Capsule)
1. Reduced coenzyme Q10 30 parts2. Pine bark extract 10 parts3. 20 parts of Tochu Nakaha Water Extract Crystalline cellulose 38 parts5. Glycerin fatty acid ester 2 parts Components 1 to 5 were mixed, and 200 mg was filled into a hard capsule to obtain a capsule.

(Prescription Example 2: Tablet)
1. Reduced coenzyme Q10 6 parts2. Pine bark extract 1 part3. Tochu Nakaha Extract 1 part4. Carboxymethylcellulose calcium 50 parts5. Corn starch 40 parts6. Talc 2 parts components 1-6 were mixed uniformly and tableted to obtain 250 mg tablets per tablet.

(Prescription Example 3: Tablet Confectionery)
1. Reduced coenzyme Q10 2.0 parts2. Pine bark extract 0.2 parts3. Tochu Nakaha Extract 2.0 parts4. Lactose 53.0 parts 5. Reduced maltose starch syrup 40.0 parts 6. Sucrose fatty acid ester 2.7 parts7. Fragrance 0.1 parts Components 1-5 are mixed, 10% water is added as a binder, fluidized bed granulated, ingredients 6 and 7 are added to the formed granules, mixed, compressed, and per tablet 500 mg of tablet confection was obtained.

(Prescription Example 4: Beverage)
1. 1. 1.0 part of reduced coenzyme Q10 Pine bark extract 0.1 part3. Tochu Nakaha Extract 1.0 part4. Sucrose 10.0 parts5. Citric acid 1.0 part6. Fragrance 0.5 part7. Components 1 to 6 were added to 86.4 parts of purified water 7 and dissolved by stirring, heat sterilized and filled into a glass bottle to obtain 20 mL of beverage per bottle.

Claims (3)

An oral composition comprising a pine bark extract, a reduced coenzyme Q10, and a Tochu extract. The oral composition according to claim 1, comprising 2 to 10 parts by weight of reduced coenzyme Q10 and 1 to 10 parts by weight of Tochu extract with respect to 1 part by weight of pine bark extract. The oral composition according to claim 1 or 2, which is a vascular condition improving composition.

Images